Male infertility is a growing concern, affecting a significant percentage of couples trying to conceive worldwide. Several factors contribute to this issue, including obesity, type 2 diabetes, and the hormonal imbalances that often accompany these conditions. These metabolic disturbances can wreak havoc on male reproductive health.
One condition closely linked to obesity and type 2 diabetes is functional hypogonadism (FH). FH is characterized by low testosterone levels in men who don’t have primary testicular failure. In other words, their testicles are capable of producing testosterone, but something else is interfering with the process.
Enter semaglutide. Semaglutide is a GLP-1 receptor agonist primarily used to treat type 2 diabetes and obesity. Recent research suggests that semaglutide may offer benefits for male fertility, particularly in the context of FH. Could this medication, typically used for weight management and blood sugar control, also play a role in improving sperm quality and hormonal balance in men?
This article will explore the current evidence surrounding semaglutide’s impact on male fertility, focusing on its effects on sperm quality, hormonal balance, and metabolic parameters. We’ll also compare its efficacy to traditional treatments like testosterone replacement therapy (TRT) to determine if semaglutide represents a promising new approach or just another potential avenue for improving male reproductive health.
Read more